In June 2018, the European Union (EU) delivered the following statement on Intellectual Property and the Public Interest at the WTO TRIPS Council. The EU voiced a specific concern over a reference in the WTO submission by China and South… Continue Reading
On Friday May 11, 2018, the Department of Health and Human Services (DHHS) held its annual listening session in advance of the upcoming Seventy-First World Health Assembly. Comments were limited to 2 minutes, with no time set aside for a… Continue Reading
The following statement can be attributed to James Love, Director, on May 11, 2018. “The Trump Administration is proposing that the U.S. government advocate higher drug prices in foreign countries. We’ll have to see the details of how this effort… Continue Reading
KEI submitted a post-hearing submission to the USTR for the Special 301 on behalf of itself and twelve other international NGOs and academic institutions condemning recent pressures on Colombia’s legal and regulatory measures to increase access to affordable medicines, including… Continue Reading
On March 12, 2018, the European Commission issued a press release on a report on the “protection and enforcement of intellectual property rights in third countries”. The report was published on February 21, 2018 and is entitled – “Commission Staff… Continue Reading
FOR IMMEDIATE RELEASE March 12, 2018 kim.treanor@keionline.org (202)-332-2670 A coalition of 16 advocacy organizations in the United States and Korea asked trade negotiators in the U.S. and Korea to reject the demands of the pharmaceutical industry, protect human rights, and… Continue Reading
There is a specialized web page on delinkage here: http://delinkage.org De-linkage can be defined in the negative, by saying that the R&D funding should not be tied to the price of the product. Progressive de-linkage means that governments implement reforms… Continue Reading
KEI page on Research and Development Cost Transparency Legislation EB142: KEI statement on Addressing the global shortage of, and access to, medicines and vaccines, January 24th, 2018 Expert Panel charts a road map for WHO’s engagement on transparency and R&D,… Continue Reading
KEI page on the World Trade Organization’s (WTO) Trade Policy Reviews All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually… Continue Reading
2000 SPECIAL 301 REPORT United States Trade Representative Charlene Barshefsky today announced the results of the 2000 “Special 301” annual review which examined in detail the adequacy and effectiveness of intellectual property protection in over 70 countries. Ambassador Barshefsky also… Continue Reading